Agenus (NASDAQ:AGEN) Price Target Raised to $6.00 at Robert W. Baird

Agenus (NASDAQ:AGEN) had its price objective hoisted by analysts at Robert W. Baird from $4.00 to $6.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Robert W. Baird’s target price would suggest a potential upside of 20.00% from the stock’s current price.

A number of other analysts have also recently issued reports on the company. B. Riley reiterated a “buy” rating on shares of Agenus in a report on Monday, April 21st. Wall Street Zen upgraded Agenus from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. Finally, HC Wainwright upgraded Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price target for the company in a report on Wednesday. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Agenus has an average rating of “Hold” and an average target price of $14.00.

Agenus Price Performance

NASDAQ:AGEN opened at $5.00 on Wednesday. The firm’s fifty day moving average price is $2.73 and its 200 day moving average price is $2.90. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The firm has a market cap of $137.09 million, a price-to-earnings ratio of -0.44 and a beta of 1.48.

Agenus (NASDAQ:AGEN) last issued its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to analysts’ expectations of $26.38 million. As a group, analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Corton Capital Inc. acquired a new position in shares of Agenus in the 4th quarter valued at $36,000. Apollon Wealth Management LLC increased its position in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock worth $38,000 after buying an additional 5,000 shares during the period. Virtu Financial LLC bought a new position in Agenus in the 4th quarter worth approximately $51,000. Acadian Asset Management LLC bought a new position in Agenus in the 1st quarter worth approximately $58,000. Finally, Bank of Montreal Can acquired a new stake in shares of Agenus during the 4th quarter worth approximately $69,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.